- Report
- March 2022
- 142 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- November 2020
- 101 Pages
Global
€21139EUR$22,000USD£18,072GBP
- Report
- June 2018
- 12 Pages
Global
From €9608EUR$10,000USD£8,215GBP
- Report
- June 2018
- 546 Pages
Global
From €21139EUR$22,000USD£18,072GBP
Epanova is a type of cardiovascular drug used to treat high triglyceride levels in adults. It is a prescription omega-3 fatty acid, which is a type of polyunsaturated fat found in fish oil. Epanova works by reducing the amount of triglycerides in the blood, which can help reduce the risk of heart attack and stroke. It is also used to reduce the risk of pancreatitis in people with very high triglyceride levels. Epanova is available in both capsule and liquid form and is taken orally.
Epanova is a relatively new drug on the market, but it has already gained traction among physicians and patients. It is generally well-tolerated and has been shown to be effective in reducing triglyceride levels.
Companies in the Epanova market include AstraZeneca, Amarin Corporation, and GlaxoSmithKline. Show Less Read more